Metastatic breast cancer remains challenging to treat because tumor cells rewire metabolism to survive and spread.

Clinical trials play a vital role in progress against breast cancer. As part of the National Clinical Trials Network sponsored by the National Cancer Institute, the Alliance for Clinical Trials in Oncology works to advance cancer research and expand access to promising screening strategies and treatments. Through its clinical trials, the Alliance helps generate the evidence needed to improve care and bring better treatment options to patients. Today, the Alliance and Alliance Foundation Trials (AFT) have eight active trials open to people with breast cancer. Each represents another opportunity to advance research, improve care, and shape the future of breast cancer treatment.

BUFFALO, NY — October 16, 2026 — A new research paper was published in Volume 13 of Oncoscience on September 24, 2026, titled “Investigating the role of 3D goggles in optimising time during deep-inspiratory breath-hold radiotherapy: A randomised study.”

Molecular imaging with ⁶⁸Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer. According to new research published in the October issue of The Journal of Nuclear Medicine, ⁶⁸Ga-HER2 PET/CT can detect changes in HER2-positive breast cancer after only two cycles of neoadjuvant treatment, enabling physicians to potentially provide information that could support earlier discussions about subsequent treatment and surgical planning.

Exposure to common chemicals may alter how normal human breast tissue develops, according to a new study. The findings suggest that exposure to some chemicals—particularly multiple bisphenols at once—may create molecular changes in breast tissue that could influence susceptibility to breast disease later in life.